Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
A

Asia Medical & Agricultural Laboratory & Research Center PCL
SET:AMARC

Watchlist Manager
Asia Medical & Agricultural Laboratory & Research Center PCL
SET:AMARC
Watchlist
Price: 2.78 THB 5.3% Market Closed
Market Cap: ฿1.2B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

AMARC Price Targets Summary
Asia Medical & Agricultural Laboratory & Research Center PCL

Wall Street analysts forecast AMARC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMARC is 4.18 THB with a low forecast of 4.14 THB and a high forecast of 4.31 THB.

AMARC Lowest Forecast
Wall Street Target
4.14 THB
49% Upside
AMARC Average Forecast
Wall Street Target
4.18 THB
50% Upside
AMARC Highest Forecast
Wall Street Target
4.31 THB
55% Upside
Lowest
Price Target
4.14 THB
49% Upside
Average
Price Target
4.18 THB
50% Upside
Highest
Price Target
4.31 THB
55% Upside
Asia Medical & Agricultural Laboratory & Research Center PCL Competitors:
Price Targets
DGL
Delegat Group Ltd
36% Upside
BKYI
BIO-Key International Inc
204% Upside
DGL
Delegat Group Ltd
36% Upside
BKYI
BIO-Key International Inc
204% Upside

Revenue
Forecast

12% / Year
Past Growth
16% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
12% / Year
Past Growth
16% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 5 years the compound annual growth rate for Asia Medical & Agricultural Laboratory & Research Center PCL's revenue is 12%. The projected CAGR for the next 3 years is 16%.

What are analyst estimates?

Operating Income
Forecast

13% / Year
Past Growth
55% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
13% / Year
Past Growth
55% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 5 years the compound annual growth rate for Asia Medical & Agricultural Laboratory & Research Center PCL's operating income is 13%. The projected CAGR for the next 3 years is 55%.

What are analyst estimates?

Net Income
Forecast

17% / Year
Past Growth
57% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
17% / Year
Past Growth
57% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 5 years the compound annual growth rate for Asia Medical & Agricultural Laboratory & Research Center PCL's net income is 17%. The projected CAGR for the next 3 years is 57%.

What are analyst estimates?

See Also

Summary
AMARC intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMARC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMARC stock valuation using valuation multiples.
Wall Street Estimates
AMARC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMARC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AMARC's stock price target?
Price Target
4.18 THB

According to Wall Street analysts, the average 1-year price target for AMARC is 4.18 THB with a low forecast of 4.14 THB and a high forecast of 4.31 THB.

What is Asia Medical & Agricultural Laboratory & Research Center PCL's Revenue forecast?
Projected CAGR
16%

For the last 5 years the compound annual growth rate for Asia Medical & Agricultural Laboratory & Research Center PCL's revenue is 12%. The projected CAGR for the next 3 years is 16%.

What is Asia Medical & Agricultural Laboratory & Research Center PCL's Operating Income forecast?
Projected CAGR
55%

For the last 5 years the compound annual growth rate for Asia Medical & Agricultural Laboratory & Research Center PCL's operating income is 13%. The projected CAGR for the next 3 years is 55%.

What is Asia Medical & Agricultural Laboratory & Research Center PCL's Net Income forecast?
Projected CAGR
57%

For the last 5 years the compound annual growth rate for Asia Medical & Agricultural Laboratory & Research Center PCL's net income is 17%. The projected CAGR for the next 3 years is 57%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 316,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.